Access to AI News Blitz has surged, and we have paused new translations for a short while to maintain service quality. Some pages may still appear in English.
Everything is readable in English, and translations are coming back soon.
Access to AI News Blitz has surged, and we have paused new translations for a short while to maintain service quality. Some pages may still appear in English.
Everything is readable in English, and translations are coming back soon.
OpenAI announced on June 3, 2026, that it is bringing new capabilities to GPT-Rosalind, a model series purpose-built for life sciences research at enterprise scale. The update merges the agentic coding and tool use of its latest GPT-5.5 with stronger intelligence for drug discovery, analysis, design, and experimental workflows.
Continue reading
The rest of this article is for AI News Blitz readers. Choose an option below to keep reading.
Already purchased? Sign in✓ Signed in — this article isn’t included in your current plan.